For DLBCL where BCL6 plays a key oncogenic role, CDK-TCIPs offer a promising therapeutic strategy that may overcome resistance mechanisms that limit the efficacy of traditional kinase inhibitors. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.